Sorrento Therapeutics SRNE · USD

Its shares trade under the ticker SRNE. It has been listed since 19 January 2007. In the fiscal year to 31 December 2022, it reported revenue of $62.8m and a net loss of $559.3m. At that date it held total assets of $472.8m and shareholders' equity of −$21.7m.

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California. The company went IPO on 2007-01-19. The firm operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Henry JiChairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, since 2006$10.1m
• Mr. Dorman FollowwillLead Independent Director$250,018
• Dr. Kim JandaDirector$82,500
• Mr. Jaisim ShahDirector$868,233
• Mr. David LemusIndependent Director$181,326
• Dr. Yue WuIndependent Director$150,000

Overall

59

Environment

59

Social

96

Governance

23

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.